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Abstract
Background: Tuberculosis (TB) in children is rarely confirmed due to the lack of effective diagnostic tools; only 10
to 15% of pediatric TB is smear positive due to paucibacillary samples and the difficulty of obtaining high-quality
specimens from children. We evaluate here the accuracy of Xpert MTB/RIF in comparison with the Micoroscopic
observation drug susceptibility (MODS) assay for diagnosis of TB in children using samples stored during a
previously reported evaluation of the MODS assay.
Methods: Ninety-six eligible children presenting with suspected TB were recruited consecutively at Pham Ngoc
Thach Hospital in Ho Chi Minh City Viet Nam between May to December 2008 and tested by Ziehl-Neelsen smear,
MODS and Mycobacterial growth Indicator (MGIT, Becton Dickinson) culture. All samples sent by the treating
clinician for testing were included in the analysis. An aliquot of processed sample deposit was stored at −20°C and
tested in the present study by Xpert MTB/RIF test. 183 samples from 73 children were available for analysis by
Xpert. Accuracy measures of MODS and Xpert were summarized.
Results: The sensitivity (%) in detecting children with a clinical diagnosis of TB for smear, MODS and Xpert were
37.9 [95% CI 25.5; 51.6], 51.7 [38.2; 65.0] and 50.0 [36.6; 63.4], respectively (per patient analysis). Xpert was
significantly more sensitive than smear (P=0.046). Testing of additional samples did not increase case detection for
MODS while testing of a second sputum sample by Xpert detected only two additional cases. The positive and
negative predictive values (%) of Xpert were 100.0 [88.0; 100.0] and 34.1 [20.5; 49.9], respectively, while those of
MODS were 96.8 [83.3; 99.9] and 33.3 [19.6; 49.5].
Conclusion: MODS culture and Xpert MTB/RIF test have similar sensitivities for the detection of pediatric TB. Xpert
MTB RIF is able to detect tuberculosis and rifampicin resistance within two hours. MODS allows isolation of cultures
for further drug susceptibility testing but requires approximately one week to become positive. Testing of multiple
samples by xpert detected only two additional cases and the benefits must be considered against costs in each
setting. Further research is required to evaluate the optimal integration of Xpert into pediatric testing algorithms.
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Background
The World Health Organisation has estimated that there
are 1 million cases of tuberculosis in children every year
[1]. Seventy-five percent of these cases occur in the 22
high TB burden countries [2]. TB in children is rarely
confirmed due to the lack of effective diagnostic tools;
only 10 to 15% of pediatric TB is smear positive due to
paucibacillary samples and the difficulty of obtaining
high-quality specimens from children [3]. HIV co-
infection further complicates diagnosis [4]. The overall
focus of National TB programmes on notification of
smear positive tuberculosis under the DOTS strategy
has thus led to a ‘chronic neglect’ of pediatric TB, under
the assumption that an overall decline in adult tubercu-
losis would also address pediatric TB [5,6]. Current best
estimates of the burden of childhood TB are based upon
multiple assumptions and the true burden of pediatric
TB is unknown.
Diagnosis of pediatric TB is principally based on the
evaluation of medical history, clinical evaluation with
chest radiography, tuberculin skin-testing and smear mi-
croscopy with mycobacterial culture where available
[7,8]. Diagnostic tests currently used for adult tubercu-
losis show low sensitivity when applied to children. Until
the advent of the Xpert MTB/RIF test, nucleic acid amp-
lification tests (NAAT) required a specialized laboratory
with rigorous quality control which can be difficult to
maintain in low resource settings. In the last decade, sig-
nificant advances have been made in the development
and implementation of novel diagnostic tests for TB in
adults [9]. However, evaluation of the applicability of
these tests for pediatric TB has not been extensive [6].
The non-commercial rapid liquid culture technique,
microscopic observation drug susceptibility (MODS)
assay [10] has a sensitivity for detection of TB in chil-
dren similar to Mycobacterial growth indicator (MGIT)
culture with faster turn-around times and can therefore
significantly increase confirmation of TB in children
compared to smear microscopy alone [11,12]. However,
the plate reading is relatively labour intensive and cul-
tures require approximately a week to become positive.
The Xpert MTB/RIF test (Cepheid, USA) has shown
sensitivity and specificity approaching that of culture in
adult sputum samples, 90.4% sensitivity and 98.4% speci-
ficity in a recent meta-analysis and has been endorsed
by the WHO for use on sputum samples [13,14].
Scale-up implementation projects are underway in a
number of countries, including Vietnam [15]. A recently
published study of 452 children with suspected TB in
South Africa, a high HIV incidence region, reported a
doubling of the case detection with Xpert MTB/RIF
compared to fluorescence smear, detecting 78% and
38%, respectively [16]. The test is a promising method to
improve the diagnosis of pediatric TB, but limited data
is available on the performance of the test with pediatric
samples and is urgently required to determine appropri-
ate applications for Xpert testing.
Vietnam is a high TB burden country with an esti-
mated incidence of 200/100 000 population and an esti-
mated 2.7% prevalence of MDR TB among new cases
[17]. Twenty five percent of the Vietnamese population
is under 15 years old [18]. In 2007, only 14.9% (59/395)
of treated pediatric TB cases had microbiological con-
firmation at Pham Ngoc Thach hospital, the tertiary
referral hospital for TB in southern Vietnam [11].
We evaluate here the accuracy of Xpert in comparison
with the MODS assay for diagnosis of TB in children
using samples stored during a previously reported evalu-
ation of the MODS assay [11].
Methods
Recruitment
This study used stored samples and data from a previ-
ously reported prospective evaluation of the MODS
assay for diagnosis of pediatric TB [11]. The protocol
was approved by the Institutional Review Board (IRB) at
Pham Ngoc Thach Hospital and the Health Services of
Ho Chi Minh City. Informed consent was not sought be-
cause the study was conducted on routine samples only
and it did not involve any intervention, additional sam-
ples or change in patient management. This patient con-
sent waiver was approved by the IRB of Pham Ngoc
Thach Hospital in the protocol.
All eligible children <16 years of age with clinical sus-
picion of tuberculosis presenting to the pediatric ward at
Pham Ngoc Thach Hospital, Ho Chi Minh City, Viet
Nam from May 2008 to December 2008 were included
in the study [11]. Any patient already receiving TB ther-
apy for more than seven days was excluded from the
study.
Children were classified into 3 diagnostic categories,
confirmed TB, probable TB or TB unlikely [11]. Chil-
dren with confirmed TB had acid-fast bacilli observed by
smear microscopy or M.tuberculosis isolated from a clin-
ical sample by MGIT culture. Children with ‘probable
TB’ had clinical symptoms consistent with TB, did not
receive any alternative diagnosis and received TB treat-
ment. Children in the ‘TB unlikely’ category recovered
without TB treatment or received an alternative con-
firmed diagnosis.
The treating clinician determined the number and type
of samples collected, following routine practice. No add-
itional samples to routine care were collected as part of
this study.
Sample processing
During the original evaluation of the MODS assay, an
aliquot of decontaminated sample deposit was stored at
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−20°C. These stored aliquots were used for current
evaluation of Xpert MTB/RIF. In total, 183 samples from
73 patients were available for analysis, including sputum
(n=126), gastric fluid (n=49), cerebral spinal fluid (CSF)
(n=5), and pleural fluid (n=3). All of these samples,
except CSF, were processed by standard decontamin-
ation using Sputaprep (NaOH –NALC 2%, Nam Khoa
Company-Viet Nam) before storage.
Smear, MGIT and MODS were performed as described
previously in accordance with standard protocols.
Ziehl-Neelsen (ZN) smear: Two drops (approximately
200 μl) of processed sample deposit were placed on a
slide and stained by ZN method according to the WHO
standard protocol [19].
MGIT: Five hundred microlitres of each deposit was
inoculated into a supplemented MGIT tube following
the manufacturer’s protocol. The culture was incubated
in Bactec MGIT 960 system at 37°C and the result auto-
matically reported.
MODS assay: MODS culture was prepared in a 48-
well-tissue-culture plate. Two hundred and fifty microli-
tres of pellet was added to 7H9 medium supplemented
with OADC and PANTA antibiotic solution. After at
least 4 days of incubation, the growth of M. tuberculosis
was recorded by reading through an inverse microscope.
Xpert MTB/RIF: The test was conducted on deconta-
minated sample deposits following the manufacturer’s
standard operating procedure. The sample volume
stored varied from 0.5 ml-1.5mls. Processed sample
deposits exceeding 0.5 ml were centrifuged at 3,000 g
for 15 minutes and excess supernatant discarded to ob-
tain a final volume of 0.5 ml. One and a half milliliters
of sample reagent was added to 0.5 ml of processed sam-
ple, and incubated at room temperature for 15 minutes
with intermittent shaking and finally added to the test
cartridge and loaded onto the machine. The result was
available after 2 hours.
For any sample with a positive result for rifampicin re-
sistance by Xpert MTB/RIF, the corresponding isolate
from the same sample isolated by MGIT or MODS cul-
ture was tested for RIF and isoniazid (INH) susceptibility
by MTBDRplus test (Hain Lifesciences, Germany) and
Bactec Mycobacterial growth indicator tube SIRE Drug
susceptibility test (MGIT SIRE DST, Becton Dickinson,
USA) following the manufacturer’s protocol [20].
Statistical analysis
Accuracy measures (sensitivity, specificity, positive and
negative predictive values) of the evaluated tests for M.
tuberculosis detection were determined using two gold
standards for the reference diagnosis. The first compari-
son was made using microbiologically confirmed TB (by
smear or MGIT) as the gold standard. The second com-
parison was made using a clinical diagnosis of TB (i.e.
confirmed or probable TB) as the gold standard. Accuracy
measures and corresponding confidence intervals were
reported both on the patient and on the sample level.
For the per patient analyses, a patient was considered
to be positive if the test showed a positive result for at
least one of the patient’s samples. Exact Pearson-Clopper
confidence intervals for accuracy measures are reported.
Comparisons between the sensitivities of different diag-
nostic tests are based on McNemar’s test with continuity
correction.
For the per sample analyses, confidence intervals for
accuracy measures and comparisons of sensitivities of
different tests are based on marginal logistic regression
with an identity link function. Of note, using marginal
models and generalized estimating equations accounts
for potential dependence between test results of samples
from the same patient. To account for the fact that spe-
cificities and positive predictive values were close to
100% leading to a separation problem for the marginal
logistic regression, we used an Agresti-Caffo-type adjust-
ment for the confidence intervals in these cases [21]. We
also calculated time-dependent sensitivity curves for
MGIT and MODS. For these, a test result was consid-
ered as positive by time t if the respective test was posi-
tive overall and reached the positive value at most t days
after sample collection. Time-dependent sensitivity
curves were estimated with the Kaplan-Meier method
and samples without a positive test result were formally
regarded as censored on day “infinity”.
The association between Ct values for probe A and smear
grade was summarized and tested based on Spearman’s
rank correlation.
All analyses were done using the statistical software R
version 2.14.0 (R Foundation for statistical computing,
Vienna, Austria). All reported confidence intervals are
two-sided 95% confidence intervals and p-values ≤ 0.05
were considered as statistically significant.
Results
The previously reported prospective evaluation of the
MODS assay for diagnosis of pediatric TB [11] included
data from 96 children but 23 children did not have a
stored aliquot available for analysis by Xpert in the
present study due to insufficient volume for storage or
the use of the stored deposit aliquot for reculture in the
original MODS study. The majority (69.6%, n=16/23) of
these were in the probable TB category. Thus, data from
73 children were included in the present analysis (Figure 1).
Almost half of these children (n=35/73, 47.9%) were
between 11 and 16 years old, with 20.5% (n=15/73)
6–10 years old and 31.5% (n=23/73) 0–5 years of age.
There were 31/73 children (42.5%) with confirmed TB,
27/73 (37.0%) with probable TB and 15/73 (20.5%) were
TB unlikely. The treating clinician determined the
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number and type of samples collected. For children aged
five years or lower, the most common sample type was
gastric aspirate, while for older children, sputum was
normally collected. Only four children had two different
sample types (Table 1).
HIV testing was not performed as part of the study,
and only eight children had an HIV test as part of rou-
tine clinical care, in accordance with normal practice at
PNT. Seven of eight children tested were HIV infected.
Amongst 183 samples from 73 children tested, there
were 2 (1.1%) Xpert tests with invalid reports and 3
(1.6%) with error reports (‘post-run analysis’ for 2 tests,
‘operation terminated’ for 1 test). Error and invalid
results were excluded from further analysis, resulting in
a total of 178 samples but this did not decrease the
number of patients (n=73).
Accuracy of Xpert MTB/RIF
Per patient analysis (n=73)
The majority of patients (86%, 63/73) submitted multiple
samples; 60% (44/73) of patients produced 3 samples
and 26% (19/73) produced 2 samples.
Figure 1 Flow-chart of patient enrolment and analysis. *All patients in ‘probable TB’ or ‘TB unlikely’ categories were Xpert negative.
Table 1 Sample types included by age of children











0 – 5 5 18 2 0 28
6 – 10 11 0 3 1 15
11 – 16 33 2 0 2 34
Total 49 20 5 3 77*
* 4 patients provided 2 sample types.
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In the ‘per patient’ analysis, Xpert showed a very simi-
lar sensitivity to MODS for both confirmed TB alone
and all TB cases (confirmed + probable), 93.5% vs. 96.8%
and 50.0% vs. 51.7%, respectively. Xpert was significantly
more sensitive than smear (p= 0.046, same p-value for
both gold standards) (Table 2). Relative to smear, seven
additional cases were detected overall by Xpert while
MODS detected eight additional cases over smear.
Therefore, only a single case was detected by MODS
which was not detected by Xpert.
The specificity of Xpert in all analyses was 100%. For
MODS culture, the specificity was 93.3% for the per pa-
tient analysis of all TB cases due to a cross-contamination
event identified by spoligotyping. Details of the con-
tamination analysis for MODS have been previously
reported [11].
Per sample analysis (n=178)
The sensitivity (%) of Xpert for detection of confirmed
TB was 79.5 [95% CI 70.6; 88.4] while it was 84.6 [95%
CI 78.1; 91.2] for MODS. The difference was not statisti-
cally significant (P=0.43). MGIT culture was significantly
(p=0.03) more sensitive than Xpert with a sensitivity of
92.3% [95% CI 87.4; 97.2]. Xpert was significantly
(p=0.01) more sensitive than smear which had a sensitiv-
ity of 53.8% [95% CI 39.8; 67.9].
Table 2 Sensitivity, specificity, positive and negative predictive values of smear, MODS, MGIT and Xpert (in%) for the









Gold standard 1 = Microbiological
confirmation
Per patient analysis (n=73)
Smear 71.0 (22/31) [52.0; 85.8]) N/a N/a 82.3 (42/51)
[69.1; 91.6]
MGIT 96.8 (30/31) [83.3; 99.9] N/a N/a 97.7 (42/43)
[87.7; 99.9]












Per sample analysis (n=178)
Smear 53.8 (42/78) [39.8; 67.9]) N/a N/a 73.5 (100/136)
[63.1; 83.9]
MGIT 92.3 (72/78) [87.4; 97.2] N/a N/a 94.3 (100/106)
[90.3; 98.4]












Gold standard 2 = Clinical diagnosis Per patient analysis (n=73)
Smear 37.9 (22/58) [25.5; 51.6] N/a N/a 29.4 (15/51)
[17.5; 43.8]
MGIT 51.7 (30/58) [38.2 ; 65.0] N/a N/a 34.9 (15/43)
[21.0; 50.9]












Per sample analysis (n=178)
Smear 30.0 (42/140) [20.1 ; 39.9] N/a N/a 27.9 (38/136)
[17.1; 38.8]
MGIT 51.4 (72/140) [40.1; 62.7] N/a N/a 35.8 (38/106)
[22.8; 48.9]












N/a=not appropriate (as 100% by definition of the gold standard).
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For all TB cases (confirmed + probable), the sensitivity
of 47.1% for MODS was also marginally higher than the
sensitivity of 44.3% for Xpert, but the difference was not
statistically significant (P=0.74). For all TB cases, the
sensitivity of MGIT was 51.4% which was not signifi-
cantly higher than Xpert (P=0.43). The difference in sen-
sitivities between Xpert and smear (sensitivity 30.0%) did
not reach statistical significance for all TB cases (P=0.09)
(Table 2).
Xpert detected 23 positive samples which were not
detected by smear, while MODS detected 27. This differ-
ence in detection of smear-negative TB was not statisti-
cally significant (p=0.24).
Xpert was negative for M.tuberculosis in 7% (3/42) of
smear-positive samples, all of which were ‘scanty’ by
smear. Among them, one pleural fluid sample was also
reported as negative by both culture methods. MODS
also did not detect M.tuberculosis in 7% (3/42) of smear
positive samples all of which were ‘scanty’. Two of them
were positive by Xpert (category very low and high).
Incremental sensitivity of MODS and Xpert using multiple
sputum samples from individual patients
We investigated the cumulative sensitivity of Xpert on
additional samples collected from all 24 TB cases (con-
firmed+probable) who provided 3 sputum samples.
Xpert detected M.tuberculosis in 50% (12/24) of first
sputum samples. Testing a second sample by Xpert
detected an additional two cases [+8.3%]. The sensitivity
did not increase with a third sputum sample. MODS
detected 62.5% (15/24) patients with the first sputum
sample but did not detect any additional cases with a
second or third sample.
Time to detection
Xpert requires 2.5 hours to return a positive result. To
reach a comparable sensitivity to the 79.5% of Xpert for
microbiologically confirmed TB, MGIT and MODS both
required around 20 days. Although MGIT culture was
the most sensitive test, it took 32 days for the last cul-
ture to turn positive and reach the per-sample sensitivity
of 92.3%. In positive samples, the median time to detec-
tion of MGIT and MODS was 8 days (IQR 7–13) and
13 days (IQR 9–18), respectively.
Correlation of Ct value and smear grade
To investigate the correlation between quantification of
bacterial load by conventional smear grading and Xpert
MTB/RIF categorisation, we stratified the Ct value of
probe A according to smear grade (Figure 2).
We found a strong negative association between Ct
values and smear grade with higher Ct values in samples
with low bacterial load (Spearman rank correlation
−0.84, p<0.001). The majority of positive samples had an
Xpert result category of medium (35.5%, 22/62), only
11.3% were high. Low or very low categories accounted
for 25.8% and 27.4%, respectively.
Sensitivity by sample type
Per sample sensitivity in sputum samples (n=123) based
on clinical diagnosis: Sputum samples were collected
from 48 patients, among whom 14 patients had two
Xpert tests and 32 had three tests. The sensitivity of
Xpert was 53.0% (53/100), [95% CI 40.2; 65.8], and mar-
ginally higher for MODS at 57% (57/100), [95% CI 44.3;
69.6%] among all TB cases (confirmed+ probable)
(P=0.70).
Per sample sensitivity in gastric fluid samples (n=47)
based on clinical diagnosis: Twenty patients had gastric
fluid samples collected for TB diagnosis, among whom
12 submitted three samples and five patients submitted
two samples. For gastric fluid samples, the sensitivity of
Xpert was equal to MODS and 9/33 (27.3%, [95% CI 9.2;
45.4]) for both tests.
Sensitivity by sample type for confirmed TB cases:
Xpert showed the same sensitivity in both sample types
in TB cases with microbiological confirmation, 80.3%
(n=55/66) in sputum and 81.8% (n=9/11) in gastric fluid
(per sample analysis).
Detection of Rifampicin resistance
Two patients were detected as infected with RIF resist-
ant strains by Xpert. The test was consistently positive
for RIF resistance for consecutive samples collected from
the same patient.
MTBDR-Plus testing confirmed both strains as resist-
ant to RIF (mutations at rpoB 526 and 531). Both strains
were also resistant to both RIF and INH, and therefore
MDR TB by MGIT SIRE. One of the two MDR strains
was classified as INH susceptible by MTBDR-Plus. Drug
resistance was not determined by MODS assay.
MTBDR-Plus was also performed on DNA extracted
from 30 isolates from samples which were positive with
M. tuberculosis/RIF susceptible by Xpert (one sample
per patient). All were susceptible to RIF by MTBDR-
Plus. There were therefore no discrepencies detected be-
tween Xpert RIF resistance detection and other tests.
There was no sample with an ‘indeterminate’ result for
RIF susceptibility by Xpert.
Discussion
Xpert MTB/RIF detected 50% of children with clinically
diagnosed pediatric TB, a 12%-increase over smear. Test-
ing of multiple samples did not increase case detection
for MODS and testing of a second sputum sample by
Xpert detected only an additional two cases. The liquid
culture techniques MODS and MGIT did not have a sig-
nificantly higher sensitivity and Xpert is a ‘same-day’ test
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while liquid culture requires at least one week to return
positive results. For maximal detection of pediatric TB,
the optimal approach appears to be pairing Xpert with
liquid culture (MGIT where available or MODS as an al-
ternative). Although culture only detected a single add-
itional case in this study, the ‘per sample’ sensitivity of
MGIT culture was 14% higher overall, and culture is
required to enable full drug susceptibility testing. In
addition, Xpert MTB/RIF is able to rapidly detect RIF
resistance. However, in this study only two patients were
infected with RIF resistant strains and no robust conclu-
sions can be drawn about the accuracy of Xpert for de-
tection of MDR in these paucibacillary samples. The
implementation of new diagnostic tests is urgently required
to improve case confirmation for pediatric TB and to re-
duce unnecessary treatment.
Sensitivity of Xpert for detection of pediatric TB was
higher in this study than two previous studies from
South Africa (20.3%) and Tanzania (33.3%) [16,22]. The
higher proportion of smear positive TB in our study sug-
gests there are important differences in the patient
populations between these studies, leading to the differ-
ent reported Xpert sensitivities. This is likely to be due
to two principal factors. Firstly, the median age of chil-
dren is higher in the present study (median 8.8 years this
study, 6 years Tanzania, 19 months South Africa) and
confirmation of pediatric TB is generally higher in older
children. For example in this study, per sample sensitiv-
ity of smear, MODS and xpert was 7.7%, 23.1% and
23.1%, respectively for children aged less than four, and
48.8%, 62.8% and 60.5% respectively, for those aged four
and above. Secondly, the present study was conducted in
a tertiary referral hospital for TB rather than a general
hospital, therefore a higher proportion of the children
were microbiologically confirmed by all methods, prob-
ably due to more advanced disease and higher bacillary
loads in the samples. All studies show that Xpert
increases sensitivity detection of pediatric TB over smear
techniques.
Our analysis of children with 3 sputum samples sug-
gests that the incremental value of testing multiple spu-
tum samples from children by Xpert is moderate, with
Figure 2 Correlation of Ct values for Xpert probe A with Ziehl-Neelsen smear grade. Probe A is the earliest probe in real time MTB/RIF
reaction.
Nhu et al. BMC Infectious Diseases 2013, 13:31 Page 7 of 9
http://www.biomedcentral.com/1471-2334/13/31
an observed 8% increase (from 50% to 58%) in sensitivity
from a second sample and none from a third. Given the
relatively high costs of Xpert testing, it is likely that re-
peat testing is only beneficial when the index of suspi-
cion is high in this population. Further research will be
needed to determine the most cost-effective algorithmic
approaches to Xpert testing in children. The optimal ap-
proach will vary by setting, depending upon available
resources and the patient population tested, including
the ages of tested children.
Gastric fluid is often sampled in children unable to
produce sputum. In samples from children with
microbiologically-confirmed TB Xpert performed well
on gastric aspirates, with a similar relative sensitivity to
liquid culture as for sputum samples (81.8% for gastric
fluid vs. 80.3% for sputum). The higher sensitivity of
both MODS and Xpert on sputum for clinically con-
firmed cases is likely due to confounding by age: gastric
aspirates were collected from younger children less likely
to yield bacilli. However, relatively few gastric aspirates
were available for analysis in this study (n=20), and more
extensive evaluations of optimal sampling strategies in
children, including string test and nasopharageal aspir-
ation techniques, are required to maximize diagnostic ef-
ficacy [23].
Test failure (invalid and error reports) has important
cost implications. The Xpert failure rate was acceptably
low in this study (2.7%) and comparable with reports
from demonstration sites [24].
Although MDR TB in children remains relatively rare,
the consequences of delayed diagnosis are grave. The
ability to rapidly detect RIF resistance in this vulnerable
population is a major advance, but care must be taken,
in light of the low positive predictive value in popula-
tions with a low MDR prevalence[25,26], to obtain con-
firmatory testing. The small number (n=2) of RIF
resistant cases detected in this study does not allow
robust conclusions to be drawn.
This study was performed on retrospective stored
samples and not all the original samples were available
for analysis which may have introduced sampling bias. It
is possible that sample storage has reduced the sensitiv-
ity of Xpert in comparison with the MODS assay, which
was performed on fresh samples. However, the results
agree with previous reports that Xpert is a excellent test
for diagnosis of pediatric TB and can be applied to both
sputum and gastric aspirate samples. Xpert should be
evaluated more widely using alternative sampling strat-
egies for diagnosis of pediatric TB.
Conclusions
In conclusion, this study shows that Xpert MTB/RIF is
an accurate test for the diagnosis of pediatric TB and
should be applied where available to this vulnerable
population.
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